Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).
创建时间：
2021-03-15
